Iterum Therapeutics plc
Develops and commercializes anti-infectives for multi-drug resistant pathogens.
ITRM | US
Overview
Corporate Details
- ISIN(s):
- IE000TTOOBX0
- LEI:
- Country:
- United States of America
- Address:
- 3 DUBLIN LANDINGS, DUBLIN 1
- Website:
- https://www.iterumtx.com/
- Sector:
- Manufacturing
Description
Iterum Therapeutics plc is a pharmaceutical company focused on developing and commercializing differentiated anti-infectives to combat multi-drug resistant (MDR) pathogens. The company's lead product is sulopenem, a novel penem anti-infective compound developed in both oral and intravenous (IV) formulations. The oral formulation, ORLYNVAH™, has received U.S. FDA approval for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women caused by designated susceptible microorganisms. ORLYNVAH™ is the first oral penem antibiotic approved in the United States, addressing the need for new treatment options against the growing threat of antibiotic-resistant bacteria.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Iterum Therapeutics plc filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Iterum Therapeutics plc
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Iterum Therapeutics plc via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
